Moreover, we observed that the Pim inhibitor SGI-1776 prevented lipopolysaccharide (LPS)-induced bone loss and tumor-associated osteolysis, which suggests that Pim1 may be a potential therapeutic target for bone resorption-related diseases. The gene discussed is PIM1; the disease is neoplasm.